Pfizer stock slumps 9% following ban on Corex cough syrup

Pharmaceutical major Pfizer and Abott have discontinued the sale and manufacture of their popular cough syrups following a new order by the Government to ban their use

by exchange4media Staff
Published - Mar 15, 2016 7:59 AM Updated: Mar 15, 2016 7:59 AM
Pfizer stock slumps 9% following ban on Corex cough syrup

Pharmaceutical major Pfizer and Abott have discontinued the sale and manufacture of their popular cough syrups like Corex and Phensedyl, respectively, following a new order by the Government to ban their use. According to reports, Health Ministry has banned about 344 fixed-dose combination drugs, including cough syrups compositions, saying they involve "risk" to humans and safer alternatives were available.  Following a ban on Corex, the stock prices of Pfizer slumped by 9%.

According to Pfizer’s BSE filing:

Late Monday evening, Corex was also trending on Twitter and there was a lot of conversation happening on social media about the latest ban.

For more updates, be socially connected with us on
WhatsApp, Instagram, LinkedIn, Twitter, Facebook & Youtube
Tags marketing

Stay updated with the latest news in the Marketing & Advertising sector with our daily newsletter

By clicking Sign Up, I agree to the Terms of Use and Privacy Policy.